Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SP
851
DELISTED
SP Plus Corporation
SP
| $26.2M | 0.02% |
617,900
+74,300
| +14% | +$3.12M |
|
|
GWPH
852
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $26.2M | 0.02% |
250,171
-49,829
| -17% | -$5.59M |
|
853
Hormel Foods
HRL
$13.4B
| $26.1M | 0.02% |
+578,900
| New | +$24.9M |
|
854
DNOW Inc
DNOW
$2.95B
| $26.1M | 0.02% |
2,322,524
+1,091,338
| +89% | +$12.2M |
|
855
QCR Holdings
QCRH
$1.75B
| $26.1M | 0.02% |
595,200
+45,700
| +8% | +$1.87M |
|
856
Hewlett Packard
HPE
$79.2B
| $26.1M | 0.02% |
+1,643,900
| New | +$26.3M |
|
857
Materion
MTRN
$5.88B
| $26.1M | 0.02% |
438,395
+46,598
| +12% | +$2.76M |
|
858
IDEX
IEX
$17.6B
| $26M | 0.02% |
151,225
+60,130
| +66% | +$9.73M |
|
859
APA Corp
APA
$14B
| $26M | 0.02% |
+1,014,154
| New | +$23M |
|
860
CRA International
CRAI
$1.07B
| $25.9M | 0.02% |
475,775
+29,200
| +7% | +$1.42M |
|
|
GRMN
861
Garmin
GRMN
$60.2B
| $25.9M | 0.02% |
265,239
-206,768
| -44% | -$19.3M |
|
862
Center Bancorp
CNOB
$1.81B
| $25.8M | 0.02% |
1,004,176
-63,100
| -6% | -$1.54M |
|
863
Generac Holdings
GNRC
$12.8B
| $25.8M | 0.02% |
256,700
+99,600
| +63% | +$9.27M |
|
|
CUK
864
DELISTED
Carnival PLC
CUK
| $25.8M | 0.02% |
535,800
-312,200
| -37% | -$13.2M |
|
865
Collegium Pharmaceutical
COLL
$913M
| $25.8M | 0.02% |
1,252,328
+505,128
| +68% | +$8.42M |
|
866
Preferred Bank
PFBC
$1.28B
| $25.8M | 0.02% |
428,855
+13,100
| +3% | +$719K |
|
867
Deluxe
DLX
$1.11B
| $25.7M | 0.02% |
515,405
-3,700
| -0.7% | -$184K |
|
868
IQVIA
IQV
$39.8B
| $25.7M | 0.02% |
166,300
-571,247
| -77% | -$83.4M |
|
|
ATH
869
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $25.7M | 0.02% |
546,228
+245,255
| +81% | +$10.7M |
|
870
Fluor
FLR
$7B
| $25.7M | 0.02% |
1,360,188
+739,974
| +119% | +$13.4M |
|
|
IBTX
871
DELISTED
Independent Bank Group, Inc.
IBTX
| $25.7M | 0.02% |
462,709
+144,900
| +46% | +$8.04M |
|
872
Adient
ADNT
$1.54B
| $25.6M | 0.02% |
1,206,745
-526,055
| -30% | -$11.7M |
|
|
PFPT
873
DELISTED
Proofpoint, Inc.
PFPT
| $25.6M | 0.02% |
223,100
+114,700
| +106% | +$13.7M |
|
874
Star Bulk Carriers
SBLK
$3.21B
| $25.6M | 0.02% |
2,166,326
+120,792
| +6% | +$1.31M |
|
|
UNVR
875
DELISTED
Univar Solutions Inc.
UNVR
| $25.6M | 0.02% |
1,054,617
-31,185
| -3% | -$706K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.